

GCDGP15 Rabbit pAb

Catalog # AP98912

Product Information

Application	IHC-P, IHC-F, IF
Primary Accession	P12273
Other Accession	P12273
Reactivity	Human
Predicted	Rat, Mouse
Host	Rabbit
Clonality	Polyclonal
Calculated MW	16572
Physical State	Liquid
Immunogen	KLH conjugated synthetic peptide derived from human GCDGP15/PIP
Epitope Specificity	51-146/146
Isotype	IgG
Purity	affinity purified by Protein A
Buffer	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
SIMILARITY	Belongs to the PIP family.
SUBUNIT	Monomer. Interacts with AZGP1.
Important Note	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
Background Descriptions	Enables IgG binding activity; aspartic-type endopeptidase activity; and identical protein binding activity. Involved in several processes, including detection of chemical stimulus involved in sensory perception of bitter taste; negative regulation of T cell apoptotic process; and proteolysis. Located in extracellular space and nucleus. [provided by Alliance of Genome Resources, Apr 2022]

Additional Information

Gene ID	5304
Other Names	BRST-2; GCDFP-15; GCDFP15; GPIP4; PIP_HUMAN; PIP; Gross cystic disease fluid protein 15 (GCDFP-15); Prolactin-induced protein; Secretory actin-binding protein (SABP); gp17; prolactin induced protein; prolactin-inducible protein; gross cystic disease fluid protein 15; secretory actin-binding protein; apocrine
Dilution	IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
Storage	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

Protein Information

Name	PIP
Synonyms	GCDFP15, GPIP4
Cellular Location	Secreted.
Tissue Location	Expressed in pathological conditions of the mammary gland and in several exocrine tissues, such as the lacrimal, salivary, and sweat glands

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.